Ozempic vs. Trulicity: Which Is Better? Side-by-Side Comparison

If your main goal is to lower blood sugar while also losing weight, Ozempic is generally the better choice. Clinical trials directly comparing Ozempic and Trulicity have shown greater average reductions in A1C and body weight with Ozempic at the doses studied.

However, if your main goal is to manage type 2 diabetes while reducing cardiovascular risks, Trulicity may be the better option for certain patients. Unlike Ozempic, Trulicity’s cardiovascular risk-reduction indication includes adults with type 2 diabetes who have multiple cardiovascular risk factors, even without established cardiovascular disease.

So, which one should you choose? It depends on your treatment priorities and medical history. Ozempic contains semaglutide, while Trulicity contains dulaglutide. Both belong to the GLP-1 receptor agonist drug class, but they differ in their clinical effectiveness and approved uses.

Ultimately, the best choice is the medication that addresses your diabetes management goals while being safe and appropriate for your individual needs.

DFWPMA offers in-person GLP-1 prescription evaluations in Texas and can prescribe GLP-1 medications at a DFWPMA location across Texas to eligible patients when medically appropriate, subject to medication availability.

Our primary care providers and endocrinologists also offer ongoing care to monitor potential side effects, address health concerns, and support patients throughout GLP-1 treatment. DFWPMA does not currently offer online GLP-1 prescriptions, an in-person evaluation is required.

Book an appointment online or call (903) 957-0082 to contact our scheduling team.

Get Prescriptions for GLP-1 Medications at a DFWPMA Location Near You!

📍 GLP-1 Prescription Providers in Fort Worth, TX

1220 W Presidio St, Fort Worth, TX 76102

Book an Appointment at Our Fort Worth Location →
📍 GLP-1 Prescription Providers in Frisco, TX

7589 Preston Rd., Suite 900, Frisco, TX 75034

Book an Appointment at Our Frisco Location →
📍 GLP-1 Prescription Providers in Sherman, TX

425 N Highland Ave., Suite 260, Sherman, TX 75092

Book an Appointment at Our Sherman Location →
📞 Call DFWPMA to Schedule

Speak with our scheduling team about GLP-1 prescription evaluations, provider availability, and appointments.

Call Us → (903) 957-0082

We accept many major insurance plans. Not sure if your plan is accepted?

Call (903) 957-0082 and our team can help verify coverage.

What Is Ozempic?

Ozempic (semaglutide) is a prescription GLP-1 receptor agonist primarily used to improve blood sugar control in adults with type 2 diabetes. It also reduces the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and certain kidney and cardiovascular outcomes in adults with type 2 diabetes and chronic kidney disease.

Ozempic works by stimulating glucose-dependent insulin secretion, reducing glucagon secretion, and slowing gastric emptying. It can also reduce appetite and promote weight loss, although Ozempic is not FDA-approved specifically for weight management.

ozempic

What Is Trulicity?

Trulicity (dulaglutide) is a prescription GLP-1 receptor agonist approved to improve blood sugar control in adults and children aged 10 years and older with type 2 diabetes. It also reduces the risk of major cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.

Trulicity works by increasing glucose-dependent insulin secretion, reducing glucagon secretion, and slowing gastric emptying. It may also promote modest weight loss in some patients, although Trulicity is not FDA-approved specifically for weight management. It is administered through a once-weekly subcutaneous injection.

Trulicity

Ozempic vs. Trulicity: Side by Side Comparison

Ozempic and Trulicity differ primarily in their blood sugar-lowering effectiveness, weight-loss potential, and approved cardiovascular and kidney-related uses. Both treat type 2 diabetes, but Ozempic generally produces greater A1C reductions and weight loss at directly compared doses, while Trulicity is also approved for pediatric patients aged 10 and older. Both require medical evaluation and ongoing monitoring.

Comparison Ozempic Trulicity
Manufacturer Novo Nordisk Eli Lilly and Company
Pricing

Manufacturer self-pay options:

  • Promotional Offers: Eligible new patients may qualify for introductory pricing starting at approximately $199 per month during certain promotional periods.
  • Standard Self-Pay: Manufacturer injection offers may range from approximately $349 to $499 per month, depending on dosage and eligibility.
  • Retail Pricing: Prices without manufacturer assistance may exceed $1,000 per month.

Manufacturer savings and retail pricing:

  • Savings Card: Eligible commercially insured patients with coverage may pay as little as $25 for a prescription covering up to three months, subject to program limits.
  • Retail Pricing: Uninsured retail prices may exceed $1,000 for a four-week supply, depending on pharmacy and dosage.
  • Eligibility: Actual costs depend on insurance coverage, savings-program requirements, and prescribed dosage.
Insurance Coverage
  • Commercial Insurance: Many plans cover Ozempic for eligible adults with type 2 diabetes.
  • Medicare Part D: Coverage may be available for medically eligible beneficiaries.
  • Weight Loss Alone: Generally not covered because Ozempic is not specifically approved for weight management.
  • Commercial Insurance: Many plans cover Trulicity for eligible patients with type 2 diabetes.
  • Medicare Part D: Coverage may be available according to plan formularies and eligibility.
  • Prior Authorization: Some insurers require documentation of diabetes diagnosis or previous treatments.
Main Purpose Improve blood sugar control in adults with type 2 diabetes. Improve blood sugar control in adults and children aged 10 years and older with type 2 diabetes.
Secondary Purposes
  • Cardiovascular Protection: Reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
  • Kidney Protection: Reduce certain kidney and cardiovascular risks in adults with type 2 diabetes and chronic kidney disease.
  • Cardiovascular Protection: Reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
  • Risk Factor Management: Reduce cardiovascular events in adults with type 2 diabetes and multiple cardiovascular risk factors, even without established cardiovascular disease.
Active Ingredient Semaglutide, a GLP-1 receptor agonist. Dulaglutide, a GLP-1 receptor agonist.
Benefits
  • Blood Sugar Control: Produces substantial reductions in blood glucose and HbA1c.
  • Weight Management: May promote clinically meaningful weight loss.
  • Cardiovascular Health: Reduces certain cardiovascular risks in eligible adults with type 2 diabetes.
  • Kidney Health: Provides demonstrated benefits in specified patients with diabetic chronic kidney disease.
  • Blood Sugar Control: Improves blood glucose and HbA1c in patients with type 2 diabetes.
  • Cardiovascular Health: Reduces major cardiovascular events in eligible adults with diabetes and cardiovascular risk factors.
  • Weight Management: May produce modest weight loss in some patients.
  • Pediatric Diabetes: Provides an approved treatment option for children aged 10 and older with type 2 diabetes.
Potential Health Risks
  • Pancreatitis: Potential acute pancreatic inflammation.
  • Gallbladder Problems: Including gallstones and gallbladder inflammation.
  • Kidney Injury: Possible dehydration-related acute kidney injury.
  • Eye Complications: Possible worsening of diabetic retinopathy.
  • Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
  • Pancreatitis: Potential acute pancreatic inflammation.
  • Gallbladder Problems: Including gallstones and gallbladder inflammation.
  • Kidney Injury: Possible dehydration-related acute kidney injury.
  • Gastrointestinal Reactions: Potentially severe digestive symptoms.
  • Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
Weight Loss Potential In the SUSTAIN 7 trial, Ozempic produced approximately 4.6–6.5 kg of average weight loss over 40 weeks at the studied doses. Results vary with dosage, patient characteristics, and treatment duration. Ozempic is not approved specifically for weight loss. In the SUSTAIN 7 trial, Trulicity produced approximately 2.3–3.0 kg of average weight loss over 40 weeks at the studied doses. Higher Trulicity doses were not evaluated in this comparison. Trulicity is not approved specifically for weight loss.
Administration
  • Injection: Subcutaneous injection once weekly.
  • Injection Sites: Abdomen, thigh, or upper arm.
  • Injection Devices: Available in prefilled injection presentations, depending on product supply.
  • Injection: Subcutaneous injection once weekly.
  • Injection Sites: Abdomen, thigh, or upper arm.
  • Injection Device: Single-dose prefilled injection pen.
Dosing Considerations
  • Starting Dose: Typically 0.25 mg weekly for four weeks.
  • Dose Escalation: Gradual increases to 0.5 mg, 1 mg, or 2 mg weekly according to treatment response.
  • Maximum Dose: 2 mg once weekly for glycemic control.
  • Starting Dose: Typically 0.75 mg once weekly.
  • Dose Escalation: Adults may increase to 1.5 mg, 3 mg, or 4.5 mg weekly based on response and tolerability.
  • Maximum Dose: 4.5 mg weekly for adults; 1.5 mg weekly for pediatric patients.
Who May Benefit Most? Adults with type 2 diabetes who need substantial A1C reduction, particularly those who may benefit from additional weight loss or meet its cardiovascular or kidney risk-reduction indications. Adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors, and children aged 10 and older who need an approved GLP-1 treatment for type 2 diabetes.
How Fast Does It Work?
  • Blood Sugar: Improvements may begin within the first weeks.
  • HbA1c: Reductions are generally assessed over approximately three months.
  • Weight Loss: Typically develops gradually over several months.
  • Blood Sugar: Improvements may begin within the first several weeks.
  • HbA1c: Reductions are generally evaluated after approximately three months.
  • Weight Changes: Modest weight loss may develop gradually over several months.
Potential Side Effects
  • Digestive: Nausea, vomiting, diarrhea, abdominal pain, and constipation.
  • Timing: Gastrointestinal symptoms frequently occur when starting treatment or increasing dosage.
  • Digestive: Nausea, diarrhea, vomiting, abdominal pain, and decreased appetite.
  • Other Effects: Fatigue and indigestion may occur.
  • Timing: Gastrointestinal symptoms frequently occur during treatment initiation and dose escalation.

Information Accuracy Disclaimer: Pricing, insurance coverage, medication availability, and other details may change over time. The information presented in this comparison reflects available information as of November 10, 2026. For the most current details, consult the medication manufacturers, your insurance provider, or a qualified healthcare professional.

Important: Both medications carry a boxed warning concerning thyroid C-cell tumors observed in rodents; whether they cause these tumors in humans is unknown. Neither should be used by patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). Treatment selection requires an individualized medical assessment. Both medications can also cause hypoglycemia when used with insulin or certain other diabetes medications.

Weight-loss evidence: In the SUSTAIN 7 clinical trial, semaglutide produced greater average reductions in body weight and HbA1c than dulaglutide after 40 weeks in adults with type 2 diabetes. Semaglutide 0.5 mg and 1 mg were compared with dulaglutide 0.75 mg and 1.5 mg, respectively. However, this trial did not compare the currently available maximum doses of either medication. Therefore, the findings should not be interpreted as a direct comparison of Ozempic 2 mg versus Trulicity 4.5 mg.

Sources:

Medical Disclaimer: This article is intended for informational and educational purposes only and provides a general comparison of Ozempic and Trulicity. It is not a substitute for professional medical advice, diagnosis, or treatment.

The safety, effectiveness, and suitability of either medication depend on individual medical history, health conditions, and treatment goals. For a comprehensive evaluation and personalized treatment recommendations, consult a qualified healthcare provider before starting, changing, or discontinuing either medication.